Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_assertion type Assertion NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_head.
- NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_assertion description "[Finally, our results have clinical implications, as inhibiting ras and/or its downstream effectors, such as AKT and STAT3/5, could provide alternative means to treat low-grade, superficial papillary bladder tumors, the most common tumor in the urinary system.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_provenance.
- NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_assertion evidence source_evidence_literature NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_provenance.
- NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_assertion SIO_000772 17256055 NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_provenance.
- NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_assertion wasDerivedFrom befree-20150227 NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_provenance.
- NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_assertion wasGeneratedBy ECO_0000203 NP232751.RAbpMWVHxjoSgReQ2lUEPsCKpuR67E0LeWGGOCKWHoi9w130_provenance.